Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval

SB15 Biosimilar To Eylea Approved Shortly After Firm Agreed Marketing Deal With Samil

 
• By David Wallace
  
Eye fibre optic rainbow
Samsung Bioepis has become the first developer with approvals for both Lucentis and Eylea biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products